Pharma Times: Diagnexia and Stratipath link up brings AI breast cancer diagnostics to UK
Diagnexia has announced a partnership with Stratipath AB to bring Stratipath Breast, an AI-based prognostic risk profiling tool, to healthcare providers across the UK and Europe.
This collaboration integrates Stratipath’s technology with Diagnexia’s digital pathology network, providing faster, more precise cancer diagnostics. The partnership aims to improve decision-making for breast cancer treatments.
Diagnexia and Stratipath Partner to Expand AI-Based Cancer Precision Diagnostics Across the UK and Europe
Diagnexia, and Stratipath AB are pleased to announce a strategic partnership. This collaboration will bring Stratipath Breast, an AI-based prognostic risk profiling tool for invasive breast cancer, to pathology laboratories, hospitals, and healthcare providers across the UK and Europe.